United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - fluticasone propionate - spray - 50microgram/1dose

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - azelastine hydrochloride; fluticasone propionate - nasal spray, suspension - fluticasone, combinations

Canada - English - Health Canada

apotex inc - fluticasone propionate - spray, metered dose - 50mcg - fluticasone propionate 50mcg - corticosteroids

Canada - English - Health Canada

teva canada limited - fluticasone propionate - metered-dose pump - 50mcg - fluticasone propionate 50mcg - corticosteroids

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 8 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 40 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 20 mg/g - inhalation, powder for - excipient ingredients: lactose monohydrate - for use in the prophylactic management of asthma in adults and children over 4 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.